27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
The brokerage expects OncoMed to share in demcizumab's potential success with Celgene, while OncoMed's co-promotion rights give the company greatest exposure to Celgene partnership.
Want Private Access to Benzinga Analyst?
Check out the latest strategies our team of experts are using every week so that you can always adapt to the market like the pros!—Get FULL Access to This Week's Webinar Here.
Redwood City-based OncoMed's lead anti-DLL4 monoclonal antibody demcizumab is actively being evaluated in combination regimens for pancreatic and non-small cell lung cancer (NSCLC).
"We believe a positive readout from the Phase 2 YOSEMITE trial in pancreatic cancer could lead partner Celgene to opt-in to the demcizumab program in early 2017, followed by readout from the Phase 2 DENALI trial in NSCLC a year later," analyst Shaunak Deepak wrote in a note.
Meanwhile, the upcoming data of vantictumab in breast cancer patients could drive Bayer's opt-in to the Wnt program in 2017.
"We regard the pancreatic cancer indication as a source of potential upside for our vantictumab estimates. We see the second Wnt pathway antagonist ipafricept as a source of potential upside," Deepak highlighted.
Further, the analyst expects GlaxoSmithKline may opt-in to develop tarextumab, as it may show activity in lung cancer despite the compound failed in pancreatic cancer trial.
"In addition to near-term opt-in milestones that could reach $172 million, we believe these partnerships could payoff with long-term benefits and free-up OncoMed's resources to pursue new development activities," Deepak added.
Deepak's $20 price target assumes $10 for demcizumab, $4 for vantictumab, $2 for tarextumab and $4 for YE16 cash of $171.50 million.
Shares of OncoMed closed Wednesday's trading at $11.87. At time of publication Thursday, OncoMed was up 1.94 percent at $12.10.
Full ratings data available on Benzinga Pro.
Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email feedback@benzinga.com with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.